{"id":3965,"date":"2016-04-22T09:27:00","date_gmt":"2016-04-22T09:27:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=3965"},"modified":"2022-04-20T09:31:55","modified_gmt":"2022-04-20T09:31:55","slug":"efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/","title":{"rendered":"Efficacy and safety of granulocyte, monocyte\/macrophage adsorptive in pediatric ulcerative colitis."},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Tarja Ruuska, Peter K\u00fcster, Lena Grahnquist, Fredrik Lindgren, Anne Vibeke Wewe, World J Gastroenterol 2016 May 7; 22(17): 4389-4396<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>To investigate efficacy and safety for granulocyte, monocyte apheresis in a population of pediatric patients with ulcerative colitis. <strong>METHODS:<\/strong> The ADAPT study was a prospective, openlabel, multicenter study in pediatric patients with moderate, active ulcerative colitis with pediatric ulcerative colitis activity index (PUCAI) of 35-64. Patients received one weekly apheresis with Adacolumn\u00ae granulocyte, monocyte\/macrophage adsorptive (GMA) apheresis over 5 consecutive weeks, optionally followed by up to 3 additional apheresis treatments over 3 consecutive weeks. The primary endpoint was the change in mean PUCAI between baseline and week 12; the secondary endpoint was improvement in PUCAI categorized as (Significant Improvement, PUCAI decrease of \u2265 35), Moderate Improvement (PUCAI decrease of 20 &lt; 35), Small Improvement (PUCAI decrease of 10 &lt; 20) or No change (PUCAI decrease of &lt; 10). <strong>RESULTS: <\/strong>Twenty-five patients (mean age 13.5 years; mean weight 47.7 kg) were enrolled. In the intention-to-treat set (ITT), the mean value for PUCAI improvement was 22.3 [95%CI: 12.9-31.6; n = 21]. In the per-protocol (PP) set, the mean improvement was 36.3 [95%CI: 31.4-41.1; n = 8]. Significant Improvement was recorded for 9 out of 20 patients (45%); 5 out of 20 patients (25%) had Moderate Improvement and one patient (5%) had No Change in PUCAI score at week 12. In the PP set, six out of eight patients (75%) showed Significant Improvement; and in two out of eight patients (25%) Moderate Improvement was recorded. The endoscopic activity index (EAI) decreased by 3 points on average. Seven (7) out of 21 (33%) patients in ITT and 4 out of 8 (50%) patients in PP have used steroids during the clinical investigation. The mean steroid dosage for these patients in the ITT set decreased from a mean 12.4 mg to 10 mg daily on average from Baseline to week 12.<strong> CONCLUSION<\/strong>: In conclusion, GMA apheresis with Adacolumn\u00ae was safe and effective in pediatric patients with moderate active Ulcerative Co\u00adlitis. The present data contribute to considering GMA apheresis as a therapeutic option in pediatric patients having failed first line therapy.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4853697\/pdf\/WJG-22-4389.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4853697\/pdf\/WJG-22-4389.pdf<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Tarja Ruuska, Peter K\u00fcster, Lena Grahnquist, Fredrik Lindgren, Anne Vibeke Wewe, World J Gastroenterol 2016 May 7; 22(17): 4389-4396 To investigate efficacy and safety for granulocyte, monocyte apheresis in a population of pediatric patients with ulcerative colitis. METHODS: The ADAPT study was a prospective, openlabel, multicenter study in pediatric patients with moderate, active ulcerative colitis [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[147],"class_list":["post-3965","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-remission"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Efficacy and safety of granulocyte, monocyte\/macrophage adsorptive in pediatric ulcerative colitis. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacy and safety of granulocyte, monocyte\/macrophage adsorptive in pediatric ulcerative colitis. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Tarja Ruuska, Peter K\u00fcster, Lena Grahnquist, Fredrik Lindgren, Anne Vibeke Wewe, World J Gastroenterol 2016 May 7; 22(17): 4389-4396 To investigate efficacy and safety for granulocyte, monocyte apheresis in a population of pediatric patients with ulcerative colitis. METHODS: The ADAPT study was a prospective, openlabel, multicenter study in pediatric patients with moderate, active ulcerative colitis [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-20T09:31:55+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/\",\"name\":\"Efficacy and safety of granulocyte, monocyte\/macrophage adsorptive in pediatric ulcerative colitis. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2016-04-22T09:27:00+00:00\",\"dateModified\":\"2022-04-20T09:31:55+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Efficacy and safety of granulocyte, monocyte\/macrophage adsorptive in pediatric ulcerative colitis. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/","og_locale":"fr_FR","og_type":"article","og_title":"Efficacy and safety of granulocyte, monocyte\/macrophage adsorptive in pediatric ulcerative colitis. - Adacyte","og_description":"Tarja Ruuska, Peter K\u00fcster, Lena Grahnquist, Fredrik Lindgren, Anne Vibeke Wewe, World J Gastroenterol 2016 May 7; 22(17): 4389-4396 To investigate efficacy and safety for granulocyte, monocyte apheresis in a population of pediatric patients with ulcerative colitis. METHODS: The ADAPT study was a prospective, openlabel, multicenter study in pediatric patients with moderate, active ulcerative colitis [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/","og_site_name":"Adacyte","article_modified_time":"2022-04-20T09:31:55+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/","name":"Efficacy and safety of granulocyte, monocyte\/macrophage adsorptive in pediatric ulcerative colitis. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2016-04-22T09:27:00+00:00","dateModified":"2022-04-20T09:31:55+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/efficacy-and-safety-of-granulocyte-monocyte-macrophage-adsorptive-in-pediatric-ulcerative-colitis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/3965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=3965"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=3965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}